Citations 4

Ibrutinib-associated necrotic nasal lesion and pulmonary infiltrates

BMJ Case Reports | January 19, 2021 | Volume: 14 | Issue: 1 | Pages: e237085

10.1136/bcr-2020-237085 | PMID 33468501

Herein, we report a case of a 68-year-old woman receiving ibrutinib for chronic lymphocytic leukaemia, who presented with septic shock and a progressive necrotic lesion on her nose. Surgical pathology of the nasal lesion revealed evidence of tissue necrosis, and both tissue and blood culture grew Pseudomonas aeruginosa. A diagnosis of ecthyma gangrenosum was made. Additional investigations also led to the discovery of invasive pulmonary aspergillosis. To our knowledge, this is the first case of ecthyma gangrenosum secondary to Pseudomonas sepsis and concurrent invasive pulmonary aspergillosis associated with ibrutinib use.
Radiologic and Pathologic Correlation in EVALI

American Journal of Roentgenology | September 2, 2020 | Volume: 215 | Issue: 5 | Pages: 1057-1064

10.2214/ajr.20.22836 | PMID 32877245

Pulmonary Injury Resulting from Vaping or e-Cigarette Use: Imaging Appearances at Presentation and Follow-up

Radiology: Cardiothoracic Imaging | August 27, 2020 | Volume: 2 | Issue: 4 | Pages: e200081

10.1148/ryct.2020200081 | PMID 33778606

Coccidioidomycosis in Patients Treated With Ruxolitinib

Open Forum Infectious Diseases | June 10, 2020 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/ofid/ofaa167 | PMID 32548203

Abstract We report 8 cases of coccidioidomycosis associated with ruxolitinib treatment. Among 135 patients living in the coccidioidal-endemic region receiving ruxolitinib, 5 cases were diagnosed after starting and 4 had extrathoracic dissemination. Periodic serological screening while on ruxolitinib is warranted for patients residing in the coccidioidal-endemic region.